These results suggested that while JAK1/2 deficiency altered the tumor-immune properties of syngeneic tumors, Ruxolitinib’s immunomodulatory effect was at least partially independent of tumor cell-intrinsic JAK signaling [35]. The gene discussed is JAK1; the disease is neoplasm.